Role of miR-181 family in regulating vascular inflammation and immunity

Trends in Cardiovascular Medicine

Volumn 24, Issue 3, 2014, Pages 105-112

  Sun, Xinghui ^a   Sit, Alan ^a   Feinberg, Mark W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 181A; MICRORNA 181B; MICRORNA 181C; MICRORNA 181D; UNCLASSIFIED DRUG;

CARDIOVASCULAR INFLAMMATION; CYTOLOGY; ENDOTHELIUM CELL; FIBROBLAST; GENE LOCATION; HEART MUSCLE CELL; HUMAN; IMMUNITY; LEUKOCYTE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

FIBROBLASTS; HUMANS; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84896706827     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2013.09.002     Document Type: Review

References (62)

1. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101:3765-3777.
2. Annane D., Bellissant E., Cavaillon J.M. Septic shock. Lancet 2005, 365:63-78.
3. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annual Review of Immunology 2000, 18:309-345.
4. Baker R.G., Hayden M.S., Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metabolism 2011, 13:11-22.
5. Balakumar P., Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovascular Toxicology 2009, 9:169-176.
6. Belkaya S., Silge R.L., Hoover A.R., et al. Dynamic modulation of thymic microRNAs in response to stress. PloS One 2011, 6:e27580.
7. Bobryshev Y.V. Dendritic cells and their role in atherogenesis. Laboratory Investigation; A Journal of technical Methods and Pathology 2010, 90:970-984.
8. Boon R.A., Hergenreider E., Dimmeler S. Atheroprotective mechanisms of shear stress-regulated microRNAs. Thrombosis and Haemostasis 2012, 108:616-620.
9. Bruemmer D., Collins A.R., Noh G., et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. The Journal of Clinical Investigation 2003, 112:1318-1331.
10. Chamorro-Jorganes A, Araldi E, Suarez Y. MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacological Research: the Official Journal of the Italian Pharmacological Society 2013;75:15-27.
11. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
12. Cui Y., Han Z., Hu Y., et al. MicroRNA-181b and microRNA-9 mediate arsenic-induced angiogenesis via NRP1. Journal of Cellular Physiology 2012, 227:772-783.
13. Das S., Ferlito M., Kent O.A., et al. Nuclear miRNA regulates the mitochondrial genome in the heart. Circulation Research 2012, 110:1596-1603.
14. de Yebenes V.G., Belver L., Pisano D.G., et al. Mir-181b negatively regulates activation-induced cytidine deaminase in B cells. The Journal of Experimental Medicine 2008, 205:2199-2206.
15. Dostal D.E., Hunt R.A., Kule C.E., et al. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. Journal of Molecular and Cellular Cardiology 1997, 29:2893-2902.
16. Dutta P., Courties G., Wei Y., et al. Myocardial infarction accelerates atherosclerosis. Nature 2012, 487:325-329.
17. Ebert P.J., Jiang S., Xie J., Li Q.J., Davis M.M. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nature Immunology 2009, 10:1162-1169.
18. Fagerlund R., Kinnunen L., Kohler M., Julkunen I., Melen K. NF-(kappa)B is transported into the nucleus by importin (alpha)3 and importin (alpha)4. The Journal of Biological Chemistry 2005, 280:15942-15951.
19. Fagerlund R., Melen K., Cao X., Julkunen I. NF-kappaB p52, RelB and c-Rel are transported into the nucleus via a subset of importin alpha molecules. Cellular Signalling 2008, 20:1442-1451.
20. Fish J.E. A primer on the role of microRNAs in endothelial biology and vascular disease. Seminars in Nephrology 2012, 32:167-175.
21. Hartmann D., Thum T. MicroRNAs and vascular (dys)function. Vascular Pharmacology 2011, 55:92-105.
22. Henao-Mejia J, Williams A, Goff LA, et al. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity 2.
23. Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. The Journal of Clinical Endocrinology and Metabolism 2012, 97:E1213-E1218.
24. Iskander K.N., Osuchowski M.F., Stearns-Kurosawa D.J., et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiological Reviews 2013, 93:1247-1288.
25. Jiang X., Ning Q., Wang J. Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts. The Journal of Physiological Sciences: JPS 2013, 63:31-38.
26. Kajstura J., Cigola E., Malhotra A., et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. Journal of Molecular and Cellular Cardiology 1997, 29:859-870.
27. Kazenwadel J., Michael M.Z., Harvey N.L. Prox1 expression is negatively regulated by miR-181 in endothelial cells. Blood 2010, 116:2395-2401.
28. Kohler M., Speck C., Christiansen M., et al. Evidence for distinct substrate specificities of importin alpha family members in nuclear protein import. Molecular and Cellular Biology 1999, 19:7782-7791.
29. Li G., Yu M., Lee W.W., et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nature Medicine 2012, 18:1518-1524.
30. Li J., Cao Y., Ma X.J., et al. Roles of miR-1-1 and miR-181c in ventricular septal defects. International Journal of Cardiology 2013.
31. Li Q.J., Chau J., Ebert P.J., et al. MiR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129:147-161.
32. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
33. Libby P. Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2012, 32:2045-2051.
34. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
35. Liu G., Min H., Yue S., Chen C.Z. Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development. PloS One 2008, 3:e3592.
36. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
37. Matsusaka T., Katori H., Inagami T., Fogo A., Ichikawa I. Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. The Journal of Clinical Investigation 1999, 103:1451-1458.
38. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
39. Nduka O.O., Parrillo J.E. The pathophysiology of septic shock. Critical Care Clinics 2009, 25:677-702. [vii].
40. Neilson J.R., Zheng G.X., Burge C.B., Sharp P.A. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes & Development 2007, 21:578-589.
41. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nature reviews. Immunology 2007, 7:803-815.
42. Remus E.W., Lyle A.N., Weiss D., et al. miR181a protects against angiotensin II-induced osteopontin expression in vascular smooth muscle cells. Atherosclerosis 2013, 228:168-174.
43. Rodriguez A., Griffiths-Jones S., Ashurst J.L., Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Research 2004, 14:1902-1910.
44. Saini H.K., Griffiths-Jones S., Enright A.J. Genomic analysis of human microRNA transcripts. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:17719-17724.
45. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:2302-2309.
46. Seeger T., Haffez F., Fischer A., et al. Immunosenescence-associated microRNAs in age and heart failure. European Journal of Heart Failure 2013, 15:385-393.
47. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circulation Research 2009, 105:1164-1176.
48. Sun X., Icli B., Wara A.K., et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. The Journal of Clinical Investigation 2012, 122:1973-1990.
49. Sun Y. Oxidative stress and cardiac repair/remodeling following infarction. The American Journal of the Medical Sciences 2007, 334:197-205.
50. Theiss A.L., Jenkins A.K., Okoro N.I., Klapproth J.M., Merlin D., Sitaraman S.V. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression. Molecular Biology of the Cell 2009, 20:4412-4423.
51. Tome-Carneiro J., Larrosa M., Yanez-Gascon M.J., et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacological Research: the Official Journal of the Italian Pharmacological Society 2013, 72C:69-82.
52. Urbich C., Kuehbacher A., Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular Research 2008, 79:581-588.
53. Vacchio M.S., Ashwell J.D. Glucocorticoids and thymocyte development. Seminars in Immunology 2000, 12:475-485.
54. Vacchio M.S., Papadopoulos V., Ashwell J.D. Steroid production in the thymus: implications for thymocyte selection. The Journal of Experimental Medicine 1994, 179:1835-1846.
55. Wang L., Kou M.C., Weng C.Y., Hu L.W., Wang Y.J., Wu M.J. Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-kappaB, and MAPK pathways. Archives of Toxicology 2012, 86:879-896.
56. Weber C., Schober A., Zernecke A. MicroRNAs in arterial remodelling, inflammation and atherosclerosis. Current Drug Targets 2010, 11:950-956.
57. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature reviews. Immunology 2008, 8:802-815.
58. Wei Y., Nazari-Jahantigh M., Neth P., Weber C., Schober A. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?. Arteriosclerosis, Thrombosis, and Vascular Biology 2013, 33:449-454.
59. Wu C., Gong Y., Yuan J., et al. MicroRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos. Journal of Lipid Research 2012, 53:2355-2363.
60. Xue Q., Guo Z.Y., Li W., et al. Human activated CD4(+) T lymphocytes increase IL-2 expression by downregulating microRNA-181c. Molecular Immunology 2011, 48:592-599.
61. Zhang X., Azhar G., Nagano K., Wei J.Y. Differential vulnerability to oxidative stress in rat cardiac myocytes versus fibroblasts. Journal of the American College of Cardiology 2001, 38:2055-2062.
62. Zietara N., Lyszkiewicz M., Witzlau K., et al. Critical role for miR-181a/b-1 in agonist selection of invariant natural killer T cells. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:7407-7412.